GSK Gates partnership
November 1, 2013
Glaxosmithkline has
announced a new joint initiative
with the Bill & Melinda Gates
Foundation, which aims to make
vaccines more resistant to heat.
Both parties will invest a
combined $1.8 milion in early
stage research into vaccine
thermostability, with the move
unveiled as part of the Vaccine
Discovery Partnership at an event
in Rio de Janeiro, Brazil.
“Developing a thermostable
adjuvant is an important and
ambitious goal,” said Emmanuel
Hanon, GSK’s senior vice president
for Vaccine Discovery and
Development.
“This partnership is the starting
point for research into an exciting
area of biomedical technology
that has the potential to overcome
a significant and long-standing
barrier to vaccine access in
developing countries,” he said.
The project will initially focus on
the adjuvant AS01 which is used
in GSK’s RTS,S malaria vaccine
candidate in late stage development.
The above article was sent to subscribers in Pharmacy Daily's issue from 01 Nov 13To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 01 Nov 13
